Title |
Current and emerging treatment options in the management of lupus
|
---|---|
Published in |
ImmunoTargets and Therapy, March 2016
|
DOI | 10.2147/itt.s40675 |
Pubmed ID | |
Authors |
Natasha Jordan, David D’Cruz |
Abstract |
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical manifestations. While the clearest guidelines for the treatment of SLE exist in the context of lupus nephritis, patients with other lupus manifestations such as neuropsychiatric, hematologic, musculoskeletal, and severe cutaneous lupus frequently require immunosuppression and/or biologic therapy. Conventional immunosuppressive agents such as mycophenolate mofetil, azathioprine, and cyclophosphamide are widely used in the management of SLE with current more rationalized treatment regimens optimizing the use of these agents while minimizing potential toxicity. The advent of biologic therapies has advanced the treatment of SLE particularly in patients with refractory disease. The CD20 monoclonal antibody rituximab and the anti-BLyS agent belimumab are now widely in use in clinical practice. Several other biologic agents are in ongoing clinical trials. While immunosuppressive and biologic agents are the foundation of inflammatory disease control in SLE, the importance of managing comorbidities such as cardiovascular risk factors, bone health, and minimizing susceptibility to infection should not be neglected. |
X Demographics
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 20% |
Unknown | 4 | 80% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Scientists | 1 | 20% |
Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 93 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 14 | 15% |
Student > Postgraduate | 9 | 10% |
Student > Bachelor | 9 | 10% |
Other | 8 | 9% |
Student > Doctoral Student | 7 | 8% |
Other | 18 | 19% |
Unknown | 28 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 44 | 47% |
Immunology and Microbiology | 6 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 4% |
Biochemistry, Genetics and Molecular Biology | 3 | 3% |
Nursing and Health Professions | 2 | 2% |
Other | 4 | 4% |
Unknown | 30 | 32% |